GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Cyclically Adjusted Book per Share

ImmuCell (ImmuCell) Cyclically Adjusted Book per Share : $4.55 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is ImmuCell Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

ImmuCell's adjusted book value per share for the three months ended in Dec. 2023 was $3.225. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.55 for the trailing ten years ended in Dec. 2023.

During the past 12 months, ImmuCell's average Cyclically Adjusted Book Growth Rate was 1.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 5.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 4.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of ImmuCell was 14.50% per year. The lowest was 0.70% per year. And the median was 5.65% per year.

As of today (2024-04-27), ImmuCell's current stock price is $5.14. ImmuCell's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $4.55. ImmuCell's Cyclically Adjusted PB Ratio of today is 1.13.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of ImmuCell was 3.18. The lowest was 0.95. And the median was 1.72.


ImmuCell Cyclically Adjusted Book per Share Historical Data

The historical data trend for ImmuCell's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell Cyclically Adjusted Book per Share Chart

ImmuCell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.79 3.86 4.18 4.47 4.55

ImmuCell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.47 4.53 4.57 4.59 4.55

Competitive Comparison of ImmuCell's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, ImmuCell's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuCell's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ImmuCell's Cyclically Adjusted PB Ratio falls into.



ImmuCell Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ImmuCell's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.225/129.4194*129.4194
=3.225

Current CPI (Dec. 2023) = 129.4194.

ImmuCell Quarterly Data

Book Value per Share CPI Adj_Book
201403 3.103 99.695 4.028
201406 3.007 100.560 3.870
201409 3.014 100.428 3.884
201412 3.058 99.070 3.995
201503 3.218 99.621 4.181
201506 3.257 100.684 4.187
201509 3.371 100.392 4.346
201512 3.474 99.792 4.505
201603 3.906 100.470 5.031
201606 3.901 101.688 4.965
201609 3.918 101.861 4.978
201612 4.069 101.863 5.170
201703 4.201 102.862 5.286
201706 4.166 103.349 5.217
201709 4.148 104.136 5.155
201712 4.309 104.011 5.362
201803 4.287 105.290 5.269
201806 4.160 106.317 5.064
201809 4.134 106.507 5.023
201812 3.904 105.998 4.767
201903 4.196 107.251 5.063
201906 4.112 108.070 4.924
201909 4.049 108.329 4.837
201912 4.019 108.420 4.797
202003 4.019 108.902 4.776
202006 3.921 108.767 4.665
202009 3.885 109.815 4.579
202012 3.916 109.897 4.612
202103 3.860 111.754 4.470
202106 4.168 114.631 4.706
202109 4.193 115.734 4.689
202112 4.208 117.630 4.630
202203 4.310 121.301 4.598
202206 4.231 125.017 4.380
202209 4.129 125.227 4.267
202212 3.922 125.222 4.053
202303 3.635 127.348 3.694
202306 3.467 128.729 3.486
202309 3.358 129.860 3.347
202312 3.225 129.419 3.225

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


ImmuCell  (NAS:ICCC) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ImmuCell's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.14/4.55
=1.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of ImmuCell was 3.18. The lowest was 0.95. And the median was 1.72.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


ImmuCell Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of ImmuCell's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuCell (ImmuCell) Business Description

Industry
Traded in Other Exchanges
Address
56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.
Executives
Bryan K. Gathagan director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen director C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin other: See Explanation of Responses C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin other: See Explanation of Responses 310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb director, officer: Vice President and CSO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams officer: Vice Pres. of Mfg Operations C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild director, 10 percent owner C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham director, officer: President and CEO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde other: Director of Sales and Marketin 56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce director 56 EVERGREEN DRIVE, PORTLAND ME 04103